• Blog Post

One significant step forward in the fight against Malaria

Publish Date

15 SEP 2017


First Subject Dosed in M5717 Phase I Trial

The M5717 PeEF2 inhibitor team has achieved a major milestone!

The first subject in the Phase I trial was dosed on September 14, 2017.

M5717 has the potential to become the first single-dose treatment for cure and prophylaxis of malaria.

Performed in Australia with healthy volunteers, the Phase I trial aims to assess the safety and obtain an early read-out of the antimalarial activity of M5717 in human to confirm the potential for single dose cure.